Arif Khan

3.5k total citations
42 papers, 2.4k citations indexed

About

Arif Khan is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pharmacology. According to data from OpenAlex, Arif Khan has authored 42 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 18 papers in Cognitive Neuroscience and 17 papers in Pharmacology. Recurrent topics in Arif Khan's work include Pain Management and Placebo Effect (17 papers), Treatment of Major Depression (16 papers) and Bipolar Disorder and Treatment (8 papers). Arif Khan is often cited by papers focused on Pain Management and Placebo Effect (17 papers), Treatment of Major Depression (16 papers) and Bipolar Disorder and Treatment (8 papers). Arif Khan collaborates with scholars based in United States, Netherlands and India. Arif Khan's co-authors include Walter A. Brown, Shirin Khan, Russell L. Kolts, Heather Warner, Kelly Schwartz, Kenneth Alper, Michael J. Detke, Craig Mallinckrodt, Ronald N. Marcus and William H. Carson and has published in prestigious journals such as PLoS ONE, American Journal of Psychiatry and Diabetes Care.

In The Last Decade

Arif Khan

41 papers receiving 2.3k citations

Peers

Arif Khan
Amir H Kalali United States
Won‐Myong Bahk South Korea
John H. Heiligenstein United States
Maximilian Huhn Germany
Atsuo Nakagawa Japan
J. Craig Nelson United States
Hans‐Jürgen Möller Germany
Tom Bschor Germany
Ichiro M Omori Japan
R. Hamish McAllister‐Williams United Kingdom
Amir H Kalali United States
Arif Khan
Citations per year, relative to Arif Khan Arif Khan (= 1×) peers Amir H Kalali

Countries citing papers authored by Arif Khan

Since Specialization
Citations

This map shows the geographic impact of Arif Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arif Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arif Khan more than expected).

Fields of papers citing papers by Arif Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arif Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arif Khan. The network helps show where Arif Khan may publish in the future.

Co-authorship network of co-authors of Arif Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Arif Khan. A scholar is included among the top collaborators of Arif Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arif Khan. Arif Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hendrickx, Iris, et al.. (2021). Take Back Control: User Privacy and Transparency Concerns in Personalized Conversational Agents. University of Twente Research Information. 2 indexed citations
2.
Khan, Arif, et al.. (2018). Decreased suicide rates in recent antidepressant clinical trials. Psychopharmacology. 235(5). 1455–1462. 18 indexed citations
3.
Thase, Michael E., Carl Gommoll, Changzheng Chen, et al.. (2017). Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectrums. 22(6). 475–483. 4 indexed citations
4.
5.
Khan, Arif, Suresh Durgam, Xiongwen Tang, et al.. (2016). Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. The Primary Care Companion For CNS Disorders. 18(2). 3 indexed citations
6.
7.
8.
Khan, Shirin, et al.. (2012). Outcome measures and serious asthma exacerbation in clinical trials of asthma controller medications. Annals of Allergy Asthma & Immunology. 108(6). 448–453. 2 indexed citations
9.
10.
Khan, Arif, et al.. (2010). Are the colors and shapes of current psychotropics designed to maximize the placebo response?. Psychopharmacology. 211(1). 113–122. 14 indexed citations
11.
Alper, Kenneth, Kelly Schwartz, Russell L. Kolts, & Arif Khan. (2007). Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports. Biological Psychiatry. 62(4). 345–354. 325 indexed citations
12.
Khan, Arif, et al.. (2007). The persistence of the placebo response in antidepressant clinical trials. Journal of Psychiatric Research. 42(10). 791–796. 52 indexed citations
13.
Khan, Arif, et al.. (2007). Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports. Neuropsychopharmacology. 32(11). 2422–2430. 15 indexed citations
14.
Cohen, Seth A., Brian Fitzgerald, Shirin Khan, & Arif Khan. (2004). The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder. The Journal of Clinical Psychiatry. 65(1). 110–113. 33 indexed citations
15.
Khan, Arif, Shirin Khan, Russell L. Kolts, & Walter A. Brown. (2003). Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA Reports. American Journal of Psychiatry. 160(4). 790–792. 251 indexed citations
16.
Storosum, Jitschak G., Barbara J. van Zwieten, Tamar Wohlfarth, et al.. (2003). Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia. Archives of General Psychiatry. 60(4). 365–365. 29 indexed citations
17.
Khan, Arif, et al.. (2002). Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. Journal of Affective Disorders. 68(2-3). 183–190. 132 indexed citations
18.
Khan, Arif, Shirin Khan, & Walter A. Brown. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics?. The International Journal of Neuropsychopharmacology. 5(3). 193–7. 102 indexed citations
19.
Khan, Arif, et al.. (2001). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. The International Journal of Neuropsychopharmacology. 4(2). 113–8. 76 indexed citations
20.
Khan, Arif, Heather Warner, & Walter A. Brown. (2000). Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials. Archives of General Psychiatry. 57(4). 311–311. 356 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amir H Kalali Breakdown of academic impact, for papers by Won‐Myong Bahk Breakdown of academic impact, for papers by John H. Heiligenstein Breakdown of academic impact, for papers by Maximilian Huhn Breakdown of academic impact, for papers by Atsuo Nakagawa Breakdown of academic impact, for papers by J. Craig Nelson Breakdown of academic impact, for papers by Hans‐Jürgen Möller Breakdown of academic impact, for papers by Tom Bschor Breakdown of academic impact, for papers by Ichiro M Omori Breakdown of academic impact, for papers by R. Hamish McAllister‐Williams
Rankless by CCL
2026